Background: This study aimed to develop the Point-of-Care Key Evidence Tool (POCKET); a multi-dimensional checklist to guide the evaluation of point-of-care tests (POCTs) incorporating validity, utility, usability, costeffectiveness and patient experience. The motivation for this was to improve the efficiency of evidence generation in POCTs and reduce the lead-time for the adoption of novel POCTs. Methods: A mixed qualitative and quantitative approach was applied. Following a literature search, a three round Delphi process was undertaken incorporating a semistructured interview study and two questionnaire rounds. Participants included clinicians, laboratory personnel, commissioners, regulators (including members of National Institute for Health and Care Excellence [NICE] committees), patients, industry representatives and methodologists. Qualitative data were analysed based on grounded theory. The final tool was revised at an expert stakeholder workshop. Results: Forty-three participants were interviewed within the semi-structured interview study, 32 participated in the questionnaire rounds and nine stakeholders attended the expert workshop. The final version of the POCKET checklist contains 65 different evidence requirements grouped into seven themes. Face validity, content validity and usability has been demonstrated. There exists a shortfall in the evidence that industry and research methodologists believe should be generated regarding POCTs and what is actually required by policy and decision makers to promote implementation into current healthcare pathways. Conclusions: This study has led to the development of POCKET, a checklist for evidence generation and synthesis in POCTs. This aims to guide industry and researchers to the evidence that is required by decision makers to facilitate POCT adoption so that the benefits they can bring to patients can be effectively realised.
Introduction
Point-of-care tests (POCTs) provide rapid results near patient or at the bedside to facilitate real time clinical decision-making. Well-established examples in clinical practice include blood glucose measurement, monitoring of anticoagulation and pregnancy testing. Technological advances have allowed more tests that were once performed in specialised laboratories, to be undertaken at the bedside, in primary care or in the patient home [1] . A POCT approach offers potential advantages such as decreased time to definitive treatment, improved cost-effectiveness, reduced training requirements and increased patient satisfaction [2] . However, barriers to the implementation of POCTs exist including the increased cost on a test-by-test basis, reduced accuracy and the associated maintenance and governance responsibilities. Many such barriers may be overcome if better evidence of their impact to clinical pathways was available. The POCT diagnostic industry is expanding rapidly with an estimated 29% share of the invitro diagnostic market and is predicted to be worth US$24 billion by 2018 [3] . It is important that this proliferation is underpinned by a robust methodological pathway that evaluates these devices in a valid, efficient and timely manner.
Quality evidence on POCTs is required for regulation, policy making and implementation. Evidence generation must be centred around the clinical pathway so that healthcare benefits, consequences of misdiagnosis and the economic impact can be properly evaluated. Accumulating appropriate evidence is an expensive, timeconsuming process that results in a substantial lead-time from innovation to clinical adoption, with some technologies never making the transition. Many pathways for the evaluation of diagnostic tests have been proposed. Lijmer et al. summarised these in their systematic review [4] highlighting that the process of diagnostic test evaluation may be cyclical in nature and evidence may not need to be acquired in a longitudinal order. Currently, the pathway for evidence generation in diagnostics is fragmented and does not follow the linear sequence of evaluations that has become mainstream for drug evaluation. Diagnostic accuracy is often established with poor methodological quality [5] and alone rarely provides sufficient justification for device adoption. Evidence is required to demonstrate the test inducing a clinical decision that subsequently affects patient outcome. Ensuring devices are easy to use and economically viable is usually performed in isolation or retrospectively, limiting their applicability. Given the considerable overlap in these methodology work streams, a multidimensional concurrent approach to evidence generation may be able to make significant efficiencies to the evidence generation pathway and avoid repetition. Improvements to the evaluation process of new diagnostic technology has been recognised as a priority need internationally. This has led to the creation of several working groups aiming to address this including the NIHR Medtech and in vitro diagnostics Co-operatives (MICs) [6] and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group: Test Evaluation [7].
Tools to improve evidence generation in diagnostic evaluation include the standards for reporting of diagnostic accuracy studies (STARD) [8] initiative to improve accuracy and completeness in diagnostic accuracy studies, the EFLM practical guide for identifying unmet clinical needs for biomarkers [9] and the Consolidated Health Economic Evaluation Reporting Standards statement (CHEERS) [10] for reporting health economic evaluations. This is paralleled in the design literature by standards published by the International Organisation for Standardisation (ISO) and British Standards (BS) including BS EN 62366 [11] that relates to usability engineering in medical devices. The National Institute for Health and Clinical Excellence has published a Diagnostics Assessment Programme Manual [12] outlining what evidence is required for their appraisal process and how this should be synthesised. However, all these standards and guidelines are specific to a particular evidence domain or stakeholder group and there is an absence of an integrated framework to present the multi-dimensional evidence "package" that is required by decision makers when evaluating new POCTs.
The aim of this study was to develop the Point-of-Care Key Evidence Tool (POCKET). This is to be a multidimensional checklist to guide the evaluation of POCTs incorporating validity, utility usability, cost-effectiveness and patient experience. The motivation for POCKET is to improve POCT adoption by providing an aid for industry and researchers when developing and evaluating POCTs so that the benefits of these devices to patients can be effectively realised.
Materials and methods
A mixed qualitative and quantitative approach was adopted. Following a literature review a Delphi consensus process was undertaken to gain an expert group consensus as to the ideal evidence requirements to support adoption decisions regarding POCTs. The methodology was modified to include an initial semi-structured interview study that allowed an in-depth exploration of how evidence is currently generated and used by different stakeholders. Emergent themes relating to evidence were then translated into a traditional Delphi questionnaire format with overall results discussed in an expert workshop. The study protocol, including how participants were recruited and interview topic guides, has been previously published [13] and is summarised in Figure 1 in keeping with the Consolidated Criteria for Reporting Qualitative Studies (COREQ) checklist [14] . Qualitative data was analysed with NVivo V.10.1.1 software (QSR International, Melbourne, Victoria, Australia). Statistics were undertaken using the Statistical Package for the Social Science version 22.0 (SPSS, Chicago, IL, USA).
The study was undertaken as described in the published protocol [10] with the exception of the following amendments. In Delphi rounds two and three the commissioner and regulator groups were amalgamated given their similar approach to evidence utilisation. A further amendment was made to the format for the expert workshop as once the complexity and length of the provisional POCKET checklist were appreciated it was felt that the planned blinded validation exercise would not be feasible. Instead participants were asked to apply the checklist to a POCT they were already familiar with. Therefore, the workshop had three aims: (1) assess the face validity (the degree to which the checklist is subjectively viewed as achieving its intent) of the POCKET checklist;
(2) assess the usability of the POCKET checklist; (3) discuss the next steps in refining and disseminating the POCKET checklist. The workshop included a presentation of the aims of the study, the emergent themes from the semi-structured interview phase and Delphi questionnaire results. Usability of the checklist was evaluated by asking the group questions from the Usability Metric for User Experience (UMUX). UMUX is a concise series of questions that has been reported to be a reliable, valid and sensitive metric to measure usability (based on the ISO 9241-11 [15] definition) and user-experience [16] . Minor amendments were made to the tool based upon the group's feedback. the evaluation of POCTs. One theme relating to POCTs in general and six relating to evidence were identified (clinical needs assessment, clinical pathway and utility, validity, usability, cost-effectiveness and efficiency in evidence generation). A summary of all emergent themes with quotations to illustrate each is presented in Table 1 . However, only themes relating to device evaluation and evidence were carried forward to round two.
Results

Delphi round one: semi-structured interviews
Delphi round two and three: summarising opinions and reaching consensus
The thematic analysis of the semi-structured interviews highlighted 68 different evidence requirements that could be used by policy or decision-makers when considering the adoption of a POCT. Each of these was included as a statement in the Delphi questionnaire. The number of participants recruited in each group is reported in Table 2 . Two rounds of the Delphi questionnaire were undertaken with two statements added to the questionnaire in round three as a result of free text comments from round two.
The number of statements carried forward in each round is shown in Table 3 . Consensus, as defined by the priori definition of Cronbach's α ≥ 0.8, was reached in both the clinician group and regulator and commissioner Table 1 : Summary of emergent themes from the semi-structured interview study (Delphi round 1).
Emergent theme Summary of theme Quotations to illustrate theme
POCTs
There was a strong sentiment that POCTs were underused and undervalued in healthcare at the present time and that their use will increase. Rather than tests in isolation their use is seen as a service or process highlighting the importance of the clinical pathway. Overall, there was agreement that increased use of POCTs may provide significant solutions to many challenges faced by healthcare systems' particular financial constraints "there is an exciting future and the question is how to plan that and pick the right tests at the right time" (Commissioner) "significant opportunity to change healthcare" (Regulator) "in some instances it's probably easier and quicker just to take a normal blood test than a point-of-care test" (Clinician)
Clinical needs assessment
The importance of establishing the clinical need for a given POCT was recognised. With developments in technology many tests can now be easily translated to POCT platforms but this does not always affect the clinical pathway. Therefore, establishing whether there is a clinical need for a test to be available at the point of care should ideally precede device development in order to maximise the chances of success. This requires an understanding of the clinical pathway. Industry outlined their approach to evaluating clinical need including expert and patient opinion, evaluating available literature and assessing disease burden. However, it was commented on that this process was not always undertaken with appropriate rigour. Pharmaceutical companies were seen to be ahead in this respect "there's too many tests out there that don't require point-of-care platforms" (Regulator)
"if there is no clinical need there is no point" (Industry representative)
Clinical pathway and utility
Almost all interviewees agreed that clinical pathway evaluation was vital to the evaluation of POCTs. This introduced the subject of test utility with participants highlighting that the evaluation of diagnostic validity alone was not enough and evidence must be provided to demonstrate that the introduction of a new test does truly affect behaviour and outcomes within a pathway. However, there were examples of clinical pathways that were so complex that complex mapping can sometimes impede the progression of a project An understanding of the clinical pathway was also felt to lead to better clinical trials that evaluate patient outcomes rather than diagnostic accuracy. Some stakeholders felt that too much investment went into demonstrating validity and industry were not investing sufficient resources to demonstrate utility "just proving a device works is not good enough" (Regulator) [what is needed is] "the translation of that evidence into a convincing story for our clinicians as to why they should be using it, and identifying what are the benefits they're going to accrue to themselves, or to the patients" (Industry Representative)
Validity
Participants reported POCTs are often less robust than laboratory testing but that accuracy and quality were improving. In most circumstances this led to a trade-off between the test's accuracy and the benefits of an early result to the clinical pathway. However, the level of accuracy required for POCTs is dependent on several other factors that device developers must consider such as the disease being tested, the environment where the test will be used and subsequent effects of inaccuracies to clinical care. There was a recognised discrepancy between the levels of accuracy obtained in a laboratory setting compared to real world use. However, it was commented that analytical performance of POCTs was sometimes chased too much to the detriment of using them, e.g. in circumstances where the level of accuracy is insignificant compared to biological variation "what is the minimum performance requirement of a test and how will the test be used in that system?" (Regulator) "I'd like to see evidence that real world users were able to get accurate measurements" (Regulator)
"If you look at the precision on point of care diagnostics, they are rarely as precise as the lab measurement. Now you don't always need the level of precision that you can get with the lab measurement." (Clinician)
Emergent theme Summary of theme Quotations to illustrate theme
Training, usability and quality control The importance of usability in the design of POCTs was widely recognised. However, very few interviewees were aware of any recognised assessment of this outside of regulatory approval, which alone was not felt to be enough to guarantee the usability of a device. It was noted that usability was dependent on who the user of a test would be and the level of training provided. Challenges were highlighted in getting "staff, nurses and doctors, to understand the need for training, certification of practice, and doing quality control" and this was closely linked to safety and quality assurance (including calibration and maintenance of devices). Standard operating protocols and the identification of operator dependent steps with risk assessment were highlighted as vital to ensuring quality in POCTs programmes "it's not just putting a test in the office, it's also about educating your colleagues about how to use it" (Clinician)
Costeffectiveness
It was recognised that POCTs frequently lead to an increased cost on a test-by-test basis when compared to clinical laboratory tests given the loss of the economy of scale. However, this had to be balanced against any potential savings to the downstream pathway created by rapid decision-making, e.g. early discharge or a reduction in complications. Commissioners made this point by describing the distinction between the "cost saving" and "resource saving" with the latter being a better way to perceive POCTs
In was noted that the costs associated with POCTs are often front-loaded and occur during implementation in the purchasing of equipment, user training and establishing a service. Social costs were also recognised such as fewer days off work for patients and 
"point-of-care can sometimes be used inappropriately and there is a cost disadvantage" (Industry Representative) Efficiency in evidence generation Many stakeholders declared that they would want evidence from a UK or local population. Others saw this as inefficiency in evidence generation and industry and researchers highlighted the frustration at the number of repetitive evaluations that are often required to evaluate a POCT In respect to who generates the evidence there was a degree of contention between interviewees, with responsibility being attributed to industry, or academic bodies or even medical colleges. However, the majority of interviewees commented on the benefits of evidence being generated in partnership either with industry-academic or industry-provider collaboration. However, the focus was on quality and there was widespread recognition of the need for appropriate funding to achieve this "healthcare systems are different and patient pathways are very different and therefore the use of a point of care test in a pathway in, say, States or Scandinavia might be very different to how its use might be in a UK setting" (Regulator) group. However, this was not achieved in the methodologist or industry group.
Expert workshop
Nine stakeholders participated in the workshop and included representation from the study group, clinicians, the trust point-of-care committee, local clinical laboratories and NICE.
The workshop participants agreed that the checklist was comprehensive and met the objectives set out. Participants had applied the checklist to devices that they were familiar with and commented that it was clear, very easy to use and did not take too much time to complete. The tool did not have any components that participants found frustrating or required repeated correction, although it was commented that industry might be daunted by the amount of evidence required by the checklist. Minor refinements to the wording of the checklist were made during the workshop. The final POCKET checklist is presented in Table 4 and consists of 64 statements that are divided into seven themes.
Discussion
This study has led to the development of POCKET, a checklist tool for evidence generation and synthesis in POCTs. Data were collected from a wide range of stakeholders with face validity, content validity and usability demonstrated through a robust mixed-method methodology. The current version of the POCKET checklist with seven themes and 64 statements is ready for dissemination and real world application. The previous tools to support evidence reporting in diagnostics discussed in the introduction have been limited to a specific focus and an overall framework for the evaluation of POCTs or any diagnostic test has been absent leading to an ineffective and inefficient evidence generation pathway. The POCKET checklist provides an evidence based framework to guide the evaluation process, in order to improve the efficacy of evidence generation and ensure that it is more relevant for decision makers.
In Delphi round three, the two groups who have the responsibility for the adoption of POCTs reached consensus as to what evidence is important to them when making decisions and, therefore, which statements should be included in the tool. However, industry representatives and the group of methodologists with expertise in the evaluation of diagnostics did not. Furthermore, there was discrepancy between the number of statements carried forward by each group into the checklist with the groups separated in the same way. Those responsible for evidence generation (industry and methodologists) put forward 48 statements each in comparison to 59 and 62 statements by the decision-making groups (clinicians, commissioners and regulators). These findings support the large degree of uncertainty regarding what evidence is needed by decision-makers to support adoption and those with a role in providing it are underestimating the breadth and detail that is required. It was expected that different stakeholder groups would have different evidence requirements and the results support his. Use of the checklist can allow the production of a tailored evidence portfolio to meet the specific needs of individual stakeholders and avoid the omission of key requirements.
This study highlights the complexity of the evaluation pathway for POCTs and the breath of evidence required. It has been observed that POCKET will have a role in identifying what evidence is missing in POCT evaluation and provides an argument for bodies such as NHS healthcare trust point-of-care committees being involved at an earlier stage with the evaluation of POCTs. Members of regulatory bodies have feedback that the checklist may provide confidence for industry to approach them for appraisal and could act as a triage tool to enter certain regulatory pathways.
The POCKET checklist will be accessed through an online platform. This will allow a rapid appraisal option whereby a completion of the checklist can be undertaken to see what evidence has already been collected and where further work is required. The planned website will also generate stakeholder specific reports (i.e. only containing the evidence that is required for each stakeholder as identified by the Delphi study) that can be disseminated to relevant parties. Furthermore, the website will provide a research tool to study the longitudinal process of evidence generation in the development of new POCTs to determine where each component of the checklist can be effectively completed. Over time this will provide a rich data source to prioritise the POCKET statements to guide where investment in evidence generation should be made and at what stage of a device's development particular evidence can be achieved. It is expected that POCKET will require refinement and this will be undertaken periodically. This study design had limitations. Semi-structured interviews allow for the interviewer to probe the topic of interest, although may be a source of bias and, therefore, the primary researcher was aware of the need to remain open to the ideas of the respondents. It is recognised that the Delphi process may lead to a compromise position rather than a true consensus. In both the semi-structured interviews and Delphi survey rounds the sample size of at least eight participants in each stakeholder group is small and the extent to which included participants will be representative is unknown. Whilst the recruitment protocol aimed to recruit a broad interdisciplinary selection of participants with purposive sampling it is acknowledged that a degree of convenience sampling was unavoidable. Patients' opinions were not included in rounds two or three. This was due to the level of expertise and knowledge required regarding the adoption of healthcare technologies to develop POCKET. In respect to the checklist, given the breadth of the study some of the statements can be seen as relatively broad, particularly relating to clinical trial design and economic modelling. Methodology appraisal was outside the scope of this study and research is underway to address some of these areas by the working bodies previously described. Finally, the majority of included stakeholders were from the UK with experience working with the NHS. Therefore, the checklist may not be sensitive to any nuances relevant to other international healthcare systems and attention will be made to evaluate this once the tool is disseminated.
The POCKET checklist represents 65 evidence requirements that when achieved provides an overall multidimensional evidence package to demonstrate a device's impact to the clinical pathway and, when justified, drive adoption. Future work will be directed at determining the weight of importance each POCKET statement carries to stakeholders so that evaluation resources can be focussed on priority areas. POCKET is now ready for real-world application with the aim of reducing the lead-time for new POCTs to reach clinical practice so that the benefits they can bring to patients and society can be effectively realised.
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